Communiqués Rein Therapeutics Inc.

Actions

RNTX

US00887A2042

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 11/09/2026			Varia. 5j.	Varia. 1 janv.
0,7850 ^USD	+0,53%		-11,71%	-32,33%

04/09	Rein Therapeutics présente un poster de dernière minute sur le LTI-03 inhalé pour la fibrose pulmonaire idiopathique au congrès 2026 de l'European Respiratory Society	CI
20/08	Rein Therapeutics reçoit la désignation " Fast Track » de la FDA pour le LTI-03 dans le traitement de la fibrose pulmonaire idiopathique	CI

Communiqués

04/09	Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress	AQ
03/09	Rein Therapeutics to Present at Upcoming September Investor Conferences	AQ
20/08	Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis	AQ
14/08	Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update	AQ
04/08	Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications	AQ
21/07	Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries	AQ
11/06	Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom	AQ
18/05	Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option	AQ
01/05	Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock	AQ
29/04	Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis	AQ
27/04	Rein Therapeutics : Amendment to Annual Report (Form 10-K/A)	PU
03/03	Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis	AQ
21/01	Rein Therapeutics : Corporate Presentation	PU
20/01	Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis	AQ
06/11	Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF	AQ
03/11	Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis	AQ
09/10/25	Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis	AQ
17/09/25	Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis	AQ
22/08/25	IPF Summit 2025: Innovating Clinical Trial Design in IPF: Lessons from LTI-03	PU
19/08/25	Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis	AQ
14/08/25	Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025	AQ
30/07/25	Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing	AQ
24/06/25	Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders	PR
21/05/25	ATS 2025: Pre-clinical Proof-of-concept of Anti-fibrotic Activity Of Caveolin-1 Scaffolding Domain Peptide LTI-03 In Ex Vivo Precision Cut Lung Slices From Patients With Idiopathic Pulmonary Fibrosis	PU
21/05/25	ATS 2025: Evaluating alveolar regenerative properties of caveolin-1 scaffolding domain (CSD) peptides in three dimensional (3D) alveolospheres from IPF and normal donor lungs	PU